Geode Capital Management LLC boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 12.7%…
Barclays PLC grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 9.7%…
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…
Hims & Hers stock is full of noise, but whats the signal for investors?…
Hims & Hers stock is full of noise, but whats the signal for investors?…
Hims & Hers stock is full of noise, but whats the signal for investors?…
Franklin Resources Inc. trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 15.9% during…
Shares in Lamb Weston (LW), Hims & Hers (HIMS), and MicroStrategy Inc. (MSTR) posted significant declines on Thursday, dropping by…
Shares in Lamb Weston (LW), Hims & Hers (HIMS), and MicroStrategy Inc.…
…
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite…
These are the stocks posting the largest moves in midday trading.…
Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in…
Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a…
Meine gestrige Vermutung hat sich bestätigt: Die FDA hat den Engpass von Tirzepatid offiziell für beendet erklärt. Gleichzeitig bleibt das…
Hims & Hers Health (NYSE:HIMS) Shares Gap Down - Heres Why…
Insider sales, FDA rulings, and sky-high valuations--why investors are split on telehealths rising star…
Shares of Hims & Hers Health, Inc. (NYSE: HIMS), the telehealth company known for offering wellness products and services, faced…
Insider sales, FDA rulings, and sky-high valuations--why investors are split on telehealths rising star…
Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is…
Hims & Hers shares tumble as FDA resolves obesity drug shortage…
Erklärt die FDA-Behörde die Engpässe bei Tirzepatid und Semaglutid am 19. Dezember für beendet – und gefährdet damit Einnahmequellen…
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Irene Becklund sold 472 shares of the firms stock…
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 78,127 shares of the firms stock…
Hims & Hers chief commercial officer sells shares worth $822,710…
Hims & Hers health PAO sells shares worth $336,348…
Hims & Hers CEO Andrew Dudum sells shares worth $6.24 million…
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) saw a significant growth in short interest during the month…
Morgan Stanley initiates Hims & Hers Health at overweight with strong revenue growth projections through 2026, citing compelling investment potential.…
Hims & Hers Health (NYSE:HIMS) Shares Gap Up - Still a Buy?…
Morgan Stanley sees Hims & Hers as a “compelling compounding investment,” projecting 30% annual revenue growth through 2026…
Morgan Stanley has initiated coverage on Hims & Hers Health, Inc. (NYSE:HIMS) with an Overweight rating and a price target…
The Morning Brief team explores the latest stock recommendations from Wall Street analysts. Mizuho analysts have upgraded Tesla (TSLA) stock…
Hims&Hers (HIMS) ist eine der spannendsten Storys, wenn es um die personalisierte Beratung bei mentalen Störungen oder Sexualkrankheiten sowie bei…
Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday. They issued an "overweight"…
Morgan Stanley sets Overweight rating on Hims & Hers stock, cites growth potential…
Morgan Stanley bullish on Hims & Hers stock, sees 30% revenue growth ahead…
Morgan Stanley analyst Craig Hettenbach initiated coverage of Hims & Hers with an Overweight rating and $42 price target The…
State Street Corp increased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by…
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine…
Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust growth…
Hims & Hers Health sees robust 2024 growth with $401.6-million Q3 revenues (+77% YoY), 2M+ subscribers and plans to exceed…
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has been given an average rating of "Hold" by the…
A new report from Hims & Hers underscores the urgency of weight loss for Americans as companies race to distribute…
Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS companies in…
…
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in Hims & Hers…
Today, Hims & Hers unveiled The Shape of America, its end of year report on how weight loss is redefining…